Status:
COMPLETED
Retinoic Acid Therapy and Regulation of Salivary and Serum IL-1β, IL-8 and MCP-1 Levels
Lead Sponsor:
Medipol University
Conditions:
Acne Vulgaris
Gingivitis and Periodontal Diseases
Eligibility:
All Genders
18-30 years
Brief Summary
This prospective cohort study analysed the effects of systemic retinoic acid use on periodontal status, salivary flow rate (SFR), and salivary and serum levels of interleukin (IL)-1β, IL-8 and monocyt...
Detailed Description
Vitamin A (isotretinoin, 13-cis-retinoic acid) and its metabolites are essential for various biological processes, including vision, development, and immune regulation. The periodontium, which consist...
Eligibility Criteria
Inclusion
- Directed to use isotretinoin 0,5 to 1 mg/kg/day for 6 months for the treatment of moderate and severe acne vulgaris or nodular acne according to the global acne rating by dermatologist
- Being at the age range of 18-30 years old
- Willing to participate to the study
- Periodontally Healthy
Exclusion
- Systemic diseases other than acne vulgaris or nodular acne
- Use of antibiotics, anti-inflammatory drugs, nonsteroidal anti-inflammatory drugs, steroids, immunosuppressants, beta-blockers, calcium channel blockers, anticoagulants, or hormonal contraceptives within 6 months prior to the initiation of the study
- Pregnancy or being lactating
- Excessive use of alcohol
- Smoking
- Received nonsurgical periodontal therapy during preceding 6 months or surgical periodontal therapy during preceding 12 months
- Have fewer than 20 natural teeth excluding third molars
- Have orthodontic appliances.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06879795
Start Date
September 1 2023
End Date
July 1 2024
Last Update
March 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medipol University
Istanbul, Turkey (Türkiye)